<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Treat Options Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Curr Treat Options Infect Dis</journal-id><journal-title-group><journal-title>Current Treatment Options in Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1523-3820</issn><issn pub-type="epub">1534-6250</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7351566</article-id><article-id pub-id-type="publisher-id">232</article-id><article-id pub-id-type="doi">10.1007/s40506-020-00232-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Viral Infections (N Malavige, Section Editor)</subject></subj-group></article-categories><title-group><article-title>Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bifani</surname><given-names>Amanda Makha</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ong</surname><given-names>Eugenia Z.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>de Alwis</surname><given-names>Ruklanthi</given-names></name><degrees>MPH, PhD</degrees><address><email>rukie.dealwis@duke-nus.edu.sg</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution>Program in Emerging Infectious Diseases, </institution><institution>Duke-NUS Medical School, </institution></institution-wrap>Singapore, Singapore </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution>Viral Research and Experimental Medicine Centre (VIREMiCS), </institution><institution>SingHealth Duke-NUS, </institution></institution-wrap>Singapore, Singapore </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>7</month><year>2020</year></pub-date><fpage>1</fpage><lpage>12</lpage><permissions><copyright-statement>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p>At the turn of the nineteenth century, yellow fever (YF) was considered the most dangerous infectious disease with high case fatality. Subsequent, mass vaccination campaigns coupled with widespread elimination of the YF mosquito vector significantly decreased YF cases and reduced outbreaks to the tropical and subtropical forested regions of Africa and South America.</p></sec><sec><title>Recent Findings</title><p>However, recent (2016) large outbreaks in Angola, Democratic Republic of Congo (DRC), and South-Eastern Brazil, where previously had been demarcated as low-risk regions, have highlighted the possibility of a rapidly changing epidemiology and the potential re-emergence of yellow fever virus (YFV). Furthermore, the first-ever importation of YFV into Asia has highlighted the potential fear of YFV emerging as a global threat.</p></sec><sec><title>Summary</title><p>In this review, we describe the changing epidemiology of YF outbreaks and highlight the use of public health policies, therapeutics, and vaccination as tools to help eliminate future YFV outbreaks.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Yellow fever</kwd><kwd>Epidemiology</kwd><kwd>Vaccination</kwd><kwd>Therapeutics</kwd><kwd>Immunity</kwd><kwd>Outbreak control</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Yellow fever (YF) is a re-emerging acute viral disease that less than a century ago was considered the most dangerous infectious disease in the world [<xref ref-type="bibr" rid="CR1">1</xref>]. YF is caused by the etiological agent, yellow fever virus (YFV), which belongs to the <italic>flavivirus</italic> genus of arboviruses. YFV exists in circulation between humans, non-human primates (NHPs), and several species of mosquito vectors [<xref ref-type="bibr" rid="CR2">2</xref>]. The presence of epizootic transmission means that YFV cannot be eradicated from the world. However, preventative vaccination campaigns with live-attenuated YFV vaccines along with widespread mosquito elimination programs have proven to be efficient at substantially reducing YF cases and outbreaks [<xref ref-type="bibr" rid="CR3">3</xref>]. Individuals infected with YFV can present with a wide spectrum of symptoms, ranging from asymptomatic infections to death, with severe cases displaying high fever, dysfunction of multiple organs (including the liver, kidneys, and heart), or hemorrhage [<xref ref-type="bibr" rid="CR4">4</xref>]. The ratio of subclinical (i.e., asymptomatic to mild symptoms) to severe cases is estimated to be 1&#x02013;70, indicating that severe cases represent only &#x0201c;the tip of the iceberg&#x0201d; [<xref ref-type="bibr" rid="CR5">5</xref>]. Mathematical models have also predicted over 200,000 annual cases of YF in high-risk areas, with case fatalities ranging from 20 to 80% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. However, due to the sporadic nature of YF outbreaks, the lack of rapid diagnostics, and the high serological cross-reactivity among co-circulating flaviviruses has meant that confirmed diagnosis is limited to reference laboratories where viral RNA can be detected using reverse transcription (RT)-PCR [<xref ref-type="bibr" rid="CR8">8</xref>&#x02022;, <xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, quantifying the true global burden of YF disease and infections has been challenging.</p><p id="Par3">The complex transmission pattern of YFV between humans, non-human primates, and its mosquito vector has shaped the epidemiology of YF. Genotypes and transmission patterns of YFV are highly divergent between Africa and South America [<xref ref-type="bibr" rid="CR2">2</xref>]. In South America, YFV strains circulate in two different cycles (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref>), i.e., (1) a sylvatic cycle between non-human primates (NHP) and rainforest-dwelling mosquitoes of the <italic>Haemagogus</italic> and <italic>Aedes</italic> species, and (2) an urban cycle where rare opportunistic forest mosquito-feeding events lead to YFV infection of humans and spread through the urban human population via the urbanized mosquito, <italic>Aedes aegypti</italic>. Africa observes an additional YFV transmission cycle known as the intermediate cycle (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>), where anthropophilic mosquitoes in the savannah regions feed on both NHPs and humans leading to constant transmission of YFV between mosquito, NHPs, and humans [<xref ref-type="bibr" rid="CR10">10</xref>]. Interestingly, compared with NHP species from Africa, NHP species in South America are far more susceptible to YFV infection with high mortality [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Map displaying major outbreaks in the past decade and the vaccine coverage in countries reported as &#x0201c;high risk&#x0201d; for YFV by WHO. Major outbreaks are defined as greater than 100 cases of YF reported to WHO. All data for global YF cases and vaccine coverage were accessed from most current estimates on the WHO website (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/yellow-fever">https://www.who.int/news-room/fact-sheets/detail/yellow-fever</ext-link>).</p></caption><graphic xlink:href="40506_2020_232_Fig1_HTML" id="MO1"/></fig></p><p id="Par4">YFV exists as seven genotypes (or major lineages), with 5 circulating in Africa and 2 in South America. Phylogenetic studies show that the African lineages have a common ancestor that then spread to discrete geographical locations and further evolved to establish the five genotypes: (1) West African I, (2) West African II, (3) East and Central African, (4) East African, and (5) Angola [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The South American genotypes I and II are thought to have evolved from the West African strains during the time of the slave trade when YFV spread to the Americas [<xref ref-type="bibr" rid="CR14">14</xref>]. Unlike flaviviruses such as dengue virus (DENV), YFV is highly stable with slow epidemic and evolutionary rates [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Due to slow evolutionary rates and constant spillover, the phylogeny of YFV isolates from NHP are genetically similar to isolates from human outbreaks [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Consequently, in South America, regular surveillance of YFV outbreaks in NHP populations can be used as an epidemic preparedness strategy [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In addition to active surveillance, elimination of future YF outbreaks requires a comprehensive understanding of the current epidemiology and the influence of control and prevention methods, such as vaccination.</p><sec id="Sec2"><title>Current epidemiology: the appearance of YF in low or non-endemic regions</title><p id="Par5">In the eighteenth and nineteenth centuries, YFV led to high rates of mortality in Africa and the Americas [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Fortunately, in the mid-1960s, Max Theiler and colleagues created the earliest versions of the live attenuated yellow fever vaccine [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Subsequently, widespread mass vaccination campaigns and mosquito control efforts significantly reduced YF outbreaks. Past public health successes led to a lax in maintaining local YF vaccination coverage leading to waning herd immunity and an eventual re-emergence of large outbreaks in West Africa in the 2000s [<xref ref-type="bibr" rid="CR22">22</xref>&#x02022;&#x02022;, <xref ref-type="bibr" rid="CR23">23</xref>]. This promoted a collaborative effort by the World Health Organization (WHO), United Nations Children&#x02019;s Fund (UNICEF), Global Alliance for Vaccines and Immunization (GAVI), and 47 YFV endemic countries to create the Yellow Fever Initiative (YFI) in 2006 [<xref ref-type="bibr" rid="CR24">24</xref>], an initiative that was primarily focused on mass YF vaccination campaigns and introduction of the vaccine into childhood immunization programs in high-risk regions. In an emergency preparedness effort, the new initiative also set up a global stockpile of YF vaccines [<xref ref-type="bibr" rid="CR25">25</xref>]. While the implementation of YFI eliminated YF outbreaks, this was short-lived as the emergence of major YF outbreaks in 2016 in regions not previously characterized as high-risk for YF cast doubts on the YFI strategy [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">In Africa prior to 2016, YFV outbreaks occurred predominantly in West and East Africa, with low or no endemicity in Central Africa (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). In 2013, highly endemic regions in Africa were estimated to have a YF burden of 130,000 cases per year, which accounted for greater than 90% of the global burden [<xref ref-type="bibr" rid="CR7">7</xref>]. It had also been observed that ambient or environmental temperatures and rainfall patterns could sustain mosquito vectors and promote the spread of YFV to regions of low endemicity [<xref ref-type="bibr" rid="CR26">26</xref>]. In December 2016, YF cases were detected in Luanda, the capital city of Angola, which was previously categorized as a low-risk region for YF. The epidemic rapidly spread from Luanda to other urban populations in Angola and crossed into the neighboring country, Democratic Republic of Congo (DRC) [<xref ref-type="bibr" rid="CR27">27</xref>]. Modeling studies predict that YFV transmission was continued for longer than usual due to the rain patterns affected by the 2016 EL Ni&#x000f1;o phenomenon [<xref ref-type="bibr" rid="CR28">28</xref>]. Emergency vaccines were deployed to affected regions, but by mid-2016 the entire global stockpile of YF vaccine doses was exhausted, and fractional dosing of the YF vaccine was implemented as an emergency measure [<xref ref-type="bibr" rid="CR29">29</xref>]. By November 2016, WHO had confirmed 962 cases and 393 deaths related to this YFV outbreak. Since Angola and DRC were previously classified as low-risk for YFV transmission, these countries had not qualified for the previous vaccination campaigns within the YFI [<xref ref-type="bibr" rid="CR24">24</xref>]. Low herd immunity, due to low YF vaccination coverage facilitated the large 2016 outbreak in Angola and DRC. As a response, the WHO revised its YFI program and implemented the new &#x0201c;EYE&#x0201d; strategy, with the goal of eliminating all global YF epidemics by 2026 [<xref ref-type="bibr" rid="CR30">30</xref>&#x02022;&#x02022;]. Since 2016, there have been outbreaks of 100 or more cases reported to WHO from Mali and Chad (2018) and Nigeria (2019). As a step towards eliminating future YF outbreaks, mass vaccination campaigns are currently being carried out in YF endemic regions where previously vaccine coverage had been poor [<xref ref-type="bibr" rid="CR22">22</xref>&#x02022;&#x02022;].</p><p id="Par7">In South America, case fatality rates from YFV infections is more than double that in Africa (40&#x02013;60% versus 20%) [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, under the YFI program, preventative vaccination campaigns in high-risk YF regions significantly reduced YFV outbreaks in humans until no major outbreak (i.e., greater than 100 cases) was detected between 2010 and 2015 in Latin America. Nevertheless, in 2016 a large YF outbreak occurred in regions of Brazil that had previously had low or no risk of YF infections and therefore, low vaccination coverage [<xref ref-type="bibr" rid="CR17">17</xref>]. Phylogenetic tracking of the epidemic strains identified the originating dissemination event to have occurred in &#x0201c;Central-West&#x0201d; region in the Brazilian state of Goi&#x000e1;s about 2&#x000a0;years prior to the outbreak [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The epidemic then moved into the state of Minas Gerais, from where it moved along two different routes (route 1 towards the east and route 2 towards the south-east) into peri-urban regions of the Brazilian megapolis, S&#x000e3;o Paulo and Rio de Janeiro [<xref ref-type="bibr" rid="CR31">31</xref>]. This led to an exponential increase in transmission leading to over 2000 confirmed cases and over 600 deaths. Molecular analysis confirmed that the 2016&#x02013;2017 epidemic strain was within the South American (SA) 1 genotype and that the epidemic resulted from direct sylvatic spill over to humans with the absence of sustained YFV transmission within the urban cycle [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Some studies have attributed the 2016 YF epidemic in YF non-endemic regions of Brazil to increased virulence of the new virus strain [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], others have blamed changing aspects of population and ecology, such as the rise in population density [<xref ref-type="bibr" rid="CR34">34</xref>], the geographical expansion of the peri-urban mosquito <italic>Aedes albopictus</italic> [<xref ref-type="bibr" rid="CR35">35</xref>], human encroachment into NHP habitats [<xref ref-type="bibr" rid="CR36">36</xref>], and global warming [<xref ref-type="bibr" rid="CR37">37</xref>]. Since the factors that promote the emergence of YFV in low or non-endemic regions are not well understood, currently, we are unable to predict the next YFV outbreak in these regions.</p><p id="Par8">It is unclear why Asia has never reported endemic YFV transmission, despite similar flaviviruses (such as DENV and Zika virus) circulating in this region. However, Asia is home to over 4 billion individuals, contains widespread prevalence of the YF mosquito vector (<italic>Aedes aegypti</italic>), and has no heard immunity against YFV (due to lack of natural circulation and vaccination) [<xref ref-type="bibr" rid="CR38">38</xref>]. Therefore, increased movement of individuals between Asia and Africa and/or South America pose a real fear that YFV might spread to Asia [<xref ref-type="bibr" rid="CR39">39</xref>]. In 2016, 11 Chinese working in Angola returned to China and imported YFV for the first time into Asia [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Despite mandatory YF immunization requirements at least 10&#x000a0;days prior to travel to YFV-endemic regions outlined by the International health regulations (IHR), 5/11 of the Chinese workers had no YF vaccination record, while 4/11 had been vaccinated &#x0003c;&#x02009;14&#x000a0;days of acquiring symptoms [<xref ref-type="bibr" rid="CR42">42</xref>] [<xref ref-type="bibr" rid="CR43">43</xref>]. As links between Asia and Africa and/or South America increase, the threat of YFV spreading to Asia becomes real. Therefore, there is an urgent need to invest in research for new YFV rapid diagnostics, therapeutics, and vaccines. Furthermore, as part of YFV epidemic preparedness, it is essential that Asian countries also strengthen YFV surveillance, implement mosquito elimination programs, and put in place measures to rapidly manufacture and deploy vaccines.</p></sec><sec id="Sec3"><title>YF vaccine: our imperfect but strongest control strategy</title><p id="Par9">The live-attenuated YF vaccine, YF17D remains the single best control measure against YFV infection and is widely regarded as one of the most successful vaccines ever developed. The YF17D strain was developed in 1936 through the tedious process of serial passaging in chicken tissue of the wildtype YFV Asibi strain isolated from a patient in Ghana. There are currently three sub-strains (17D-204, 17D-213, and 17DD) licensed for use in individuals aged 9&#x000a0;months to 60&#x000a0;years old, residing in or traveling to YF-endemic regions. For all substrains of YF vaccines, antibodies against YFV are currently the gold standard when examining correlates of protection against future infection [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Protective titers were originally determined by passive immune transfer and subsequent challenge with YFV in monkeys [<xref ref-type="bibr" rid="CR46">46</xref>]. A log neutralization index (LNI) of 0.7 or higher is protective. However, calculating LNI requires pre and post vaccine serum, which is not always feasible in the context of natural infection or mass vaccination. Consequently, plaque reduction neutralizing titer (PRNT) assays have replaced LNI measurements, where an 80 or 90% PRNT (i.e., PRNT<sub>80</sub> PRNT<sub>90</sub>) is used to indicate protection [<xref ref-type="bibr" rid="CR47">47</xref>]. However, both YFV LNI and PRNT are slow, tedious, not standardizable, require experienced laboratory staff, and are limited to Biosafety level-3 containment facilities [<xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, currently, we are urgently in need of new rapid, high-throughput, easy-to-use techniques that can be used to accurately assess protective antibodies following vaccination.</p><p id="Par10">Recent epidemiological studies have expanded our understanding of factors that affect YF vaccination-induced human antibody responses (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Historically, YF vaccine studies conducted in healthy adults demonstrated that a single subcutaneous dose elicits a remarkably high seroconversion (nearly 100%) [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>]. However, recent studies show that age has a large influence on seroconversion rates, as observed by the high rates of vaccine failure in infants (9&#x02013;12&#x000a0;months) and the elderly (&#x0003e;&#x02009;60&#x000a0;years) [<xref ref-type="bibr" rid="CR52">52</xref>&#x02022;&#x02022;, <xref ref-type="bibr" rid="CR53">53</xref>]. In particular, seroconversion rates of children who received the YF vaccine in conjunction with the routine childhood vaccines for measles-mumps-rubella (MMR) had a lower seroconversion rate (69%) as compared with children who received the YF vaccine alone (~&#x02009;85%) [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Additionally, seroconversion rates in non-endemic countries (98.9%) tend to exceed seroconversion rates in endemic countries (94.2%) [<xref ref-type="bibr" rid="CR50">50</xref>]. Whether, the observed difference in seroconversion rates between endemic versus non-endemic countries is due to host genetics [<xref ref-type="bibr" rid="CR56">56</xref>], exposure to other circulating flaviviruses [<xref ref-type="bibr" rid="CR1">1</xref>], microbiome, additional co-infections that alter host immune response [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>] or host nutritional status remains to be elucidated.<fig id="Fig2"><label>Fig. 2</label><caption><p>Determinants of Yellow Fever live attenuated vaccine immunity. Schematic diagram illustrating different elements of the YF vaccine (dosage, vaccine strain, vaccine handling, i.e., cold chain), environment (endemic vs non-endemic regions, co-infection, heterologous flavivirus exposure) and host (age, genetics, microbiome) that could influence host immune response outcome to YF vaccination. Created with <ext-link ext-link-type="uri" xlink:href="http://biorender.com">BioRender.com</ext-link>.</p></caption><graphic xlink:href="40506_2020_232_Fig2_HTML" id="MO2"/></fig></p><p id="Par11">Duration of immunity and the need for a booster has been highly debated in past years, with arguments for [<xref ref-type="bibr" rid="CR59">59</xref>] and against a YF booster vaccination [<xref ref-type="bibr" rid="CR60">60</xref>]. In controversial studies carried out in non-endemic countries, it had been reported that YF17D offer long-term sero-protection lasting up to 30&#x02013;40&#x000a0;years post vaccination [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Therefore, in 2012 the WHO Strategic Advisory Group of Experts on immunization declared that a single dose of YF vaccine was sufficient for long-term protection in 2012 [<xref ref-type="bibr" rid="CR63">63</xref>]. However, more recently a substantial number of studies have highlighted that neutralizing antibody titers as well as cellular immunity wane with time [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. In adults, sero-positivity decreases at just 5&#x02013;9&#x000a0;years post vaccination from 100% down to 82% [<xref ref-type="bibr" rid="CR59">59</xref>]. This trend of waning immunity is further exaggerated at around 10&#x000a0;years post-vaccination with sero-protection dropping under 80% in both endemic [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR65">65</xref>] and non-endemic cohorts [<xref ref-type="bibr" rid="CR64">64</xref>]. Furthermore, waning immunity in children vaccinated between 9 and 12&#x000a0;months of age is more severe with only ~&#x02009;40% retaining long-term sero-protection (~&#x02009;6&#x000a0;years post vaccination) in Brazil [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>] and Ghana [<xref ref-type="bibr" rid="CR52">52</xref>&#x02022;&#x02022;]. Surprisingly, a retrospective study in Brazil between 1973 and 2008 noted that the number of hospitalised YF cases with a history of YF vaccination over 10 years prior to illness and without past YF vaccination (52% vs 45%, respectively) was not significantly different [<xref ref-type="bibr" rid="CR47">47</xref>]. In fact, vaccination coverage of up to 95% may be required for high-risk regions to eliminate yellow fever outbreaks [<xref ref-type="bibr" rid="CR66">66</xref>]. These disturbing observations are further evidence of waning YF vaccine immunity over time, and thus provides strong support that a YF booster vaccination is needed (i.e., a 10-year vaccination booster for travelers [<xref ref-type="bibr" rid="CR67">67</xref>] and a 4-to-5-year booster for children vaccinated during their first year of life).</p><p id="Par12">Following the global shortage of YF vaccine supplies in 2016, in an effort to maximize vaccination coverage and to curtail the epidemics in Angola and DRC, public health officials proceeded to conduct fractional dosing of the remaining YF vaccines [<xref ref-type="bibr" rid="CR68">68</xref>]. Studies in <italic>Rhesus macaques</italic> showed fractional dosing of YF17D to be effective in protecting against wildtype Asibi in a challenge model [<xref ref-type="bibr" rid="CR46">46</xref>]. In humans, a tenfold lower dose of YF17D provoked a similar cytokine profile, viremia, and PRNT response as a standard dose [<xref ref-type="bibr" rid="CR69">69</xref>]. Compared with full dose, fractional dosing of YF17D stimulated similar seroconversion rates [<xref ref-type="bibr" rid="CR70">70</xref>] that persisted for 10&#x000a0;months to 1&#x000a0;year post-vaccination [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Long-term protection was observed in 98% of patients receiving a fractional dose in a non-endemic setting [<xref ref-type="bibr" rid="CR73">73</xref>], while only 85% of recipients in an endemic region maintained lasting immunity [<xref ref-type="bibr" rid="CR74">74</xref>]. Overall, the decision to use fractional dosing in an outbreak setting was supported by the prediction that during the 2016 YF epidemic in Angola a lack of fractional dosing would have led to a 5.1-fold increase in mortality due to YF [<xref ref-type="bibr" rid="CR28">28</xref>]. However, our understanding of the effect of fractional dosing on waning immunity, on vaccine shelf-life, on the antibody responses in different age groups and genetic background are limited [<xref ref-type="bibr" rid="CR68">68</xref>]. Hence, it is imperative that we continue to improve our evidence base to understand the effect of YF vaccine dose-fractionation on protection against YFV infections.</p><p id="Par13">The role of T cell immunity in yellow fever vaccination remains unclear. Not surprisingly, YF vaccination induces strong CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses, which persists for several years following vaccination [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. CD4<sup>+</sup> T cell expansion occurs earlier and with a greater magnitude after vaccination than CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>]. Epidemiological evidence shows that seroconversion rates drop and immunity wanes rapidly following YF vaccination of HIV positive patients, whose CD4<sup>+</sup> T cell response is impaired [<xref ref-type="bibr" rid="CR78">78</xref>]. While these studies suggest that T cells contribute to the maintenance of sero-protection and flaviviral clearance, it is likely that T cell immunity alone is insufficient to confer protection [<xref ref-type="bibr" rid="CR47">47</xref>]. Furthermore, immunization with the chimeric flavivirus vaccine on a YF17D backbone of non-structural proteins did not offer protection when challenged with YFV [<xref ref-type="bibr" rid="CR79">79</xref>]. On the other hand, passive transfer of antibodies was sufficient for protection against wildtype infection [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par14">Therefore, it is likely that although both B and T cells play a role in establishing viral clearance, antibody responses play a more dominant role in eliciting YF vaccine-induced protection.</p><p id="Par15">In terms of vaccine safety, YF vaccination has been associated with several rare but related adverse events (AEs) particularly in the elderly (&#x02265;&#x02009;60&#x000a0;years old) [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>]. Vaccine-associated neurotropic disease (YFV-AND) causes neurological complications that are typically not fatal. However, vaccine-associated viscerotropic disease (YFV-AVD) results in an infection that resembles natural YF disease accompanied by a high fatality rate. Virus isolated from YFV-AVD patients do not have any mutations in the YF17D genome [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>], thus the driver of YFV-AVD remains unknown. AEs tend to be reported more frequently in non-endemic countries, possibly as a result of under-reporting in endemic countries [<xref ref-type="bibr" rid="CR47">47</xref>]. Additionally, host genetics [<xref ref-type="bibr" rid="CR56">56</xref>], egg allergies (due to the manufacturing process) [<xref ref-type="bibr" rid="CR80">80</xref>], and an active immune environment [<xref ref-type="bibr" rid="CR58">58</xref>] have been linked with disease outcome and could contribute to the frequency of adverse events experienced by different populations. At the same time, YF vaccines unknowingly administered to pregnant women were immunogenic and elicited varying degrees of sero-protection without harming or trans-placentally infecting the fetus, illustrating the safety profile of YF vaccines during pregnancy [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Therefore, given the low incidence of AEs in high-risk areas, and the large risk of mortality associated with YF infections, the threat from wildtype YFV infections outweighs that from YF vaccine-associated AEs [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par16">The EYE&#x02019;s initiative aims to eliminate YF through vaccination of 1 billion people living in at-risk areas by 2026. Unfortunately, these efforts have been thwarted by vaccine shortages. The ambitious EYEs initiative assumes that a single dose confers life-long immunity, yet as discussed above this is likely not the case. It is estimated that 90 million doses of the YF17D vaccine are needed every year. Due to the slow, tedious, and low-yielding process of manufacturing YF vaccine doses in chicken embryos [<xref ref-type="bibr" rid="CR1">1</xref>], the production capability is limited and unable to meet increased demands during an outbreak or booster vaccination campaigns. Efforts are being made to develop new vaccines with higher yields and increased safety profiles [<xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR90">90</xref>]. The most promising of which is a cell culture (Vero cell)-based production of an inactivated YFV vaccine [<xref ref-type="bibr" rid="CR91">91</xref>]. The inactivated vaccine showed promising results in clinical trials [<xref ref-type="bibr" rid="CR91">91</xref>], but was less immunogenic than the live-attenuated YF vaccines and required a two-dose schedule with an adjuvant. Ideally, a new cell culture method for YF17D that increases yields and cuts production time, while maintaining efficacy, genomic stability, and safety would be required to meet the world&#x02019;s growing demands for the vaccine.</p></sec><sec id="Sec4"><title>A possible role for therapeutics in YF control?</title><p id="Par17">There are no approved therapeutics against YFV infections and treatment of YF disease is reliant on supportive care to alleviate disease symptoms. Although its initial clinical presentation may be benign, 15% of symptomatic patients can rapidly progress to severe yellow fever that requires intensive care support [<xref ref-type="bibr" rid="CR92">92</xref>]. This includes the prophylactic use of anticonvulsant drugs to reduce the frequency of seizures and the use of intravenous proton pump inhibitors to treat gastric bleeding [<xref ref-type="bibr" rid="CR93">93</xref>]. While there are licensed YF vaccines, as discussed above mass immunization programs have been hampered by global vaccine shortages. Against this backdrop, an effective antiviral against YFV could be used as a treatment (to significantly improve the clinical outlook for patients with severe YF) and also as an outbreak control strategy (i.e., as prophylaxis when YF vaccine is in short supply).</p><p id="Par18">Drug repurposing has been adopted as a strategy for identifying de-risked compounds that have demonstrated safety profile in preclinical models or humans, with potential time saved for drug development [<xref ref-type="bibr" rid="CR94">94</xref>]. Although there are currently no approved antivirals for the treatment or prevention of YF, there are several repurposed candidates in the drug development pipeline. Galidesivir and Sofosbuvir are both nucleoside analog antivirals originally used to treat chronic hepatitis C infections, which have emerged as promising antivirals for the treatment of YF [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Both Galidesivir and Sofosbuvir were found to inhibit YF replication in vitro and in vivo in rodent animal models [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Interestingly, the therapeutic administration of Galidesivir allowed the development of neutralizing antibodies against YFV that completely protected against secondary YFV challenge, highlighting that the use of these drugs will not hamper the development of adaptive immunity [<xref ref-type="bibr" rid="CR97">97</xref>]. Following the completion of Phase IA clinical trial to evaluate the safety and tolerability of intravenous Galidesivir in healthy volunteers, a Phase IB study that aims to evaluate antiviral effects of intravenous Galidesivir in YF patients is currently ongoing (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> NCT03891420). Recently, two YFV-infected patients presenting with acute liver failure were treated off-label with Sofosbuvir for a week as compassionate use and displayed marked reduction in viremia and improved liver function [<xref ref-type="bibr" rid="CR99">99</xref>]. Furthermore, in recent years, virus-neutralizing monoclonal antibodies (mAbs) have also been recognized as a treatment modality for YF [<xref ref-type="bibr" rid="CR100">100</xref>]. The candidate that is most advanced in clinical development is TY014, which has currently completed Phase 1A/1B safety trials (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> NCT03776786). As antivirals against YFV become licensed for use in patients and travelers, it is hoped that these will contribute to both treatment of YF disease and the control of YF outbreaks.</p></sec></sec><sec id="Sec5"><title>Conclusion</title><p id="Par19">The re-emergence of outbreaks in low-risk areas and importation of cases to Asia indicate the rapidly changing epidemiology of YF. As part of epidemic preparedness, efforts should be directed at enhancing YF surveillance, diagnostic capabilities of laboratories and improving vaccine coverage, even in low endemic regions. While the live attenuated YF vaccine is highly efficacious, vaccine supply shortfalls due to limited production suggest that the development of new vaccines and improved manufacturing technologies will be urgently needed to meet increased worldwide demand. Lastly, a two-pronged approach that combines vaccination and therapeutic interventions will be paramount to prevent the re-emergence of future YF outbreaks.</p></sec></body><back><fn-group><fn><p>This article is part of the Topical Collection on <italic>Viral Infections</italic></p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par20">Amanda Makha Bifani declares that she has no conflict of interest. Eugenia Z. Ong declares that she has no conflict of interest. Ruklanthi de Alwis declares that she has no conflict of interest.</p></notes><notes id="FPar2"><title>Human and animal rights and informed consent</title><p id="Par21">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes></notes><ref-list id="Bib1"><title>References and Recommended Reading</title><ref-list id="BSec1"><title>Papers of particular interest, published recently, have been highlighted as: &#x02022; Of importance &#x02022;&#x02022; Of major importance</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Vasconcelos</surname><given-names>PF</given-names></name></person-group><article-title>Yellow fever</article-title><source>J Clin Virol</source><year>2015</year><volume>64</volume><fpage>160</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.08.030</pub-id><?supplied-pmid 25453327?><pub-id pub-id-type="pmid">25453327</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staples</surname><given-names>JE</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name></person-group><article-title>Yellow fever: 100 years of discovery</article-title><source>JAMA.</source><year>2008</year><volume>300</volume><issue>8</issue><fpage>960</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1001/jama.300.8.960</pub-id><?supplied-pmid 18728272?><pub-id pub-id-type="pmid">18728272</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frierson</surname><given-names>JG</given-names></name></person-group><article-title>The yellow fever vaccine: a history</article-title><source>Yale J Biol Med</source><year>2010</year><volume>83</volume><issue>2</issue><fpage>77</fpage><lpage>85</lpage><?supplied-pmid 20589188?><pub-id pub-id-type="pmid">20589188</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quaresma</surname><given-names>JA</given-names></name><name><surname>Pagliari</surname><given-names>C</given-names></name><name><surname>Medeiros</surname><given-names>DB</given-names></name><name><surname>Duarte</surname><given-names>MI</given-names></name><name><surname>Vasconcelos</surname><given-names>PF</given-names></name></person-group><article-title>Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever</article-title><source>Rev Med Virol</source><year>2013</year><volume>23</volume><issue>5</issue><fpage>305</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1002/rmv.1752</pub-id><?supplied-pmid 23873723?><pub-id pub-id-type="pmid">23873723</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>MA</given-names></name><name><surname>Vasconcelos</surname><given-names>PF</given-names></name><name><surname>Staples</surname><given-names>JE</given-names></name></person-group><article-title>The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases</article-title><source>Trans R Soc Trop Med Hyg</source><year>2014</year><volume>108</volume><issue>8</issue><fpage>482</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1093/trstmh/tru092</pub-id><?supplied-pmid 24980556?><pub-id pub-id-type="pmid">24980556</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>FM</given-names></name><name><surname>Longbottom</surname><given-names>J</given-names></name><name><surname>Browne</surname><given-names>AJ</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Marinho</surname><given-names>F</given-names></name><name><surname>Yactayo</surname><given-names>S</given-names></name><name><surname>de Ara&#x000fa;jo</surname><given-names>VEM</given-names></name><name><surname>da N&#x000f3;brega</surname><given-names>AA</given-names></name><name><surname>Fullman</surname><given-names>N</given-names></name><name><surname>Ray</surname><given-names>SE</given-names></name><name><surname>Mosser</surname><given-names>JF</given-names></name><name><surname>Stanaway</surname><given-names>JD</given-names></name><name><surname>Lim</surname><given-names>SS</given-names></name><name><surname>Reiner</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Moyes</surname><given-names>CL</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Golding</surname><given-names>N</given-names></name></person-group><article-title>Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis</article-title><source>Lancet Glob Health</source><year>2018</year><volume>6</volume><issue>3</issue><fpage>e270</fpage><lpage>e2e8</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(18)30024-X</pub-id><?supplied-pmid 29398634?><pub-id pub-id-type="pmid">29398634</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garske</surname><given-names>T</given-names></name><name><surname>Van Kerkhove</surname><given-names>MD</given-names></name><name><surname>Yactayo</surname><given-names>S</given-names></name><name><surname>Ronveaux</surname><given-names>O</given-names></name><name><surname>Lewis</surname><given-names>RF</given-names></name><name><surname>Staples</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data</article-title><source>PLoS Med</source><year>2014</year><volume>11</volume><issue>5</issue><fpage>e1001638</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001638</pub-id><?supplied-pmid 24800812?><pub-id pub-id-type="pmid">24800812</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingo</surname><given-names>C</given-names></name><name><surname>Charrel</surname><given-names>RN</given-names></name><name><surname>Schmidt-Chanasit</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>H</given-names></name><name><surname>Reusken</surname><given-names>C</given-names></name></person-group><article-title>Yellow fever in the diagnostics laboratory</article-title><source>Emerg Microbes Infect</source><year>2018</year><volume>7</volume><issue>1</issue><fpage>129</fpage><pub-id pub-id-type="doi">10.1038/s41426-018-0128-8</pub-id><?supplied-pmid 30002363?><pub-id pub-id-type="pmid">30002363</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingelbeen</surname><given-names>B</given-names></name><name><surname>Weregemere</surname><given-names>NA</given-names></name><name><surname>Noel</surname><given-names>H</given-names></name><name><surname>Tshapenda</surname><given-names>GP</given-names></name><name><surname>Mossoko</surname><given-names>M</given-names></name><name><surname>Nsio</surname><given-names>J</given-names></name><name><surname>Ronsse</surname><given-names>A</given-names></name><name><surname>Ahuka-Mundeke</surname><given-names>S</given-names></name><name><surname>Cohuet</surname><given-names>S</given-names></name><name><surname>Kebela</surname><given-names>BI</given-names></name></person-group><article-title>Urban yellow fever outbreak-Democratic Republic of the Congo, 2016: towards more rapid case detection</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><issue>12</issue><fpage>e0007029</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0007029</pub-id><?supplied-pmid 30532188?><pub-id pub-id-type="pmid">30532188</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrington</surname><given-names>CV</given-names></name><name><surname>Auguste</surname><given-names>AJ</given-names></name></person-group><article-title>Evolutionary and ecological factors underlying the tempo and distribution of yellow fever virus activity</article-title><source>Infect Genet Evol</source><year>2013</year><volume>13</volume><fpage>198</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.08.015</pub-id><?supplied-pmid 22981999?><pub-id pub-id-type="pmid">22981999</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>N</given-names></name><name><surname>Cunha</surname><given-names>MS</given-names></name><name><surname>Guerra</surname><given-names>JM</given-names></name><name><surname>Ressio</surname><given-names>RA</given-names></name><name><surname>Cirqueira</surname><given-names>CDS</given-names></name><name><surname>Iglezias</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Outbreak of yellow fever among nonhuman primates, Espirito Santo, Brazil, 2017</article-title><source>Emerg Infect Dis</source><year>2017</year><volume>23</volume><issue>12</issue><fpage>2038</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.3201/eid2312.170685</pub-id><?supplied-pmid 29148378?><pub-id pub-id-type="pmid">29148378</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>NIO</given-names></name><name><surname>Sacchetto</surname><given-names>L</given-names></name><name><surname>de Rezende</surname><given-names>IM</given-names></name><name><surname>Trindade</surname><given-names>GS</given-names></name><name><surname>LaBeaud</surname><given-names>AD</given-names></name><name><surname>de Thoisy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease</article-title><source>Virol J</source><year>2020</year><volume>17</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12985-019-1277-7</pub-id><?supplied-pmid 31973727?><pub-id pub-id-type="pmid">31973727</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutebi</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Bryant</surname><given-names>JE</given-names></name><name><surname>Barrett</surname><given-names>AD</given-names></name></person-group><article-title>Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa</article-title><source>J Virol</source><year>2001</year><volume>75</volume><issue>15</issue><fpage>6999</fpage><lpage>7008</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.15.6999-7008.2001</pub-id><?supplied-pmid 11435580?><pub-id pub-id-type="pmid">11435580</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>JE</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Barrett</surname><given-names>AD</given-names></name></person-group><article-title>Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas</article-title><source>PLoS Pathog</source><year>2007</year><volume>3</volume><issue>5</issue><fpage>e75</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0030075</pub-id><?supplied-pmid 17511518?><pub-id pub-id-type="pmid">17511518</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>du</surname><given-names>P</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Phylogenomic analysis unravels evolution of yellow fever virus within hosts</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><issue>9</issue><fpage>e0006738</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006738</pub-id><?supplied-pmid 30188905?><pub-id pub-id-type="pmid">30188905</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kum</surname><given-names>DB</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Vrancken</surname><given-names>B</given-names></name><name><surname>Thibaut</surname><given-names>HJ</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Lemey</surname><given-names>P</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Dallmeier</surname><given-names>K</given-names></name></person-group><article-title>Limited evolution of the yellow fever virus 17d in a mouse infection model</article-title><source>Emerg Microbes Infect</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>1734</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1080/22221751.2019.1694394</pub-id><?supplied-pmid 31797751?><pub-id pub-id-type="pmid">31797751</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>PO</given-names></name><name><surname>Silva</surname><given-names>ATS</given-names></name><name><surname>Oliveira</surname><given-names>JS</given-names></name><name><surname>Marinho</surname><given-names>PE</given-names></name><name><surname>Rocha</surname><given-names>FT</given-names></name><name><surname>Domingos</surname><given-names>GP</given-names></name><name><surname>Poblete</surname><given-names>PCP</given-names></name><name><surname>Oliveira</surname><given-names>LBS</given-names></name><name><surname>Duarte</surname><given-names>DC</given-names></name><name><surname>Bonjardim</surname><given-names>CA</given-names></name><name><surname>Abrah&#x000e3;o</surname><given-names>JS</given-names></name><name><surname>Kroon</surname><given-names>EG</given-names></name><name><surname>Drumond</surname><given-names>BP</given-names></name><name><surname>Oliveira</surname><given-names>DB</given-names></name><name><surname>Trindade</surname><given-names>GS</given-names></name></person-group><article-title>Detection and molecular characterization of yellow fever virus, 2017</article-title><source>Brazil Ecohealth</source><year>2018</year><volume>15</volume><issue>4</issue><fpage>864</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1007/s10393-018-1364-z</pub-id><?supplied-pmid 30117000?><pub-id pub-id-type="pmid">30117000</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>IM</given-names></name><name><surname>Sacchetto</surname><given-names>L</given-names></name><name><surname>Munhoz de Mello</surname><given-names>E</given-names></name><name><surname>Alves</surname><given-names>PA</given-names></name><name><surname>Iani</surname><given-names>FCM</given-names></name><name><surname>Adelino</surname><given-names>TER</given-names></name><etal/></person-group><article-title>Persistence of Yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><issue>6</issue><fpage>e0006538</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006538</pub-id><?supplied-pmid 29864115?><pub-id pub-id-type="pmid">29864115</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mares-Guia</surname><given-names>M</given-names></name><name><surname>Horta</surname><given-names>MA</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>CDS</given-names></name><name><surname>Mendonca</surname><given-names>MCL</given-names></name><name><surname>Dos Santos</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Yellow fever epizootics in non-human primates, southeast and northeast Brazil (2017 and 2018)</article-title><source>Parasit Vectors</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>90</fpage><pub-id pub-id-type="doi">10.1186/s13071-020-3966-x</pub-id><?supplied-pmid 32075684?><pub-id pub-id-type="pmid">32075684</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douam</surname><given-names>F</given-names></name><name><surname>Ploss</surname><given-names>A</given-names></name></person-group><article-title>Yellow fever virus: knowledge gaps impeding the fight against an old foe</article-title><source>Trends Microbiol</source><year>2018</year><volume>26</volume><issue>11</issue><fpage>913</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.05.012</pub-id><?supplied-pmid 29933925?><pub-id pub-id-type="pmid">29933925</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norrby</surname><given-names>E</given-names></name></person-group><article-title>Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><issue>12</issue><fpage>2779</fpage><lpage>2784</lpage><pub-id pub-id-type="doi">10.1084/jem.20072290</pub-id><?supplied-pmid 18039952?><pub-id pub-id-type="pmid">18039952</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>FM</given-names></name><name><surname>Moyes</surname><given-names>CL</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Marinho</surname><given-names>F</given-names></name><name><surname>Deshpande</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><issue>11</issue><fpage>1209</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30419-X</pub-id><?supplied-pmid 28822780?><pub-id pub-id-type="pmid">28822780</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>DJ</given-names></name><name><surname>Wilson</surname><given-names>AJ</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Graham</surname><given-names>AJ</given-names></name></person-group><article-title>The global distribution of yellow fever and dengue</article-title><source>Adv Parasitol</source><year>2006</year><volume>62</volume><fpage>181</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/S0065-308X(05)62006-4</pub-id><?supplied-pmid 16647971?><pub-id pub-id-type="pmid">16647971</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">WHO. Yellow fever initiative providing an opportunity of a lifetime. In: Organization WH, editor. Geneva 2010.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">WHO. International coordination group on vaccine provision for yellow fever. In: Organization WH, editor. Geneva 2019.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamlet</surname><given-names>A</given-names></name><name><surname>Jean</surname><given-names>K</given-names></name><name><surname>Perea</surname><given-names>W</given-names></name><name><surname>Yactayo</surname><given-names>S</given-names></name><name><surname>Biey</surname><given-names>J</given-names></name><name><surname>Van Kerkhove</surname><given-names>M</given-names></name><etal/></person-group><article-title>The seasonal influence of climate and environment on yellow fever transmission across Africa</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><issue>3</issue><fpage>e0006284</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006284</pub-id><?supplied-pmid 29543798?><pub-id pub-id-type="pmid">29543798</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Faria</surname><given-names>NR</given-names></name><name><surname>Reiner</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Golding</surname><given-names>N</given-names></name><name><surname>Nikolay</surname><given-names>B</given-names></name><name><surname>Stasse</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>MA</given-names></name><name><surname>Salje</surname><given-names>H</given-names></name><name><surname>Faye</surname><given-names>O</given-names></name><name><surname>Wint</surname><given-names>GRW</given-names></name><name><surname>Niedrig</surname><given-names>M</given-names></name><name><surname>Shearer</surname><given-names>FM</given-names></name><name><surname>Hill</surname><given-names>SC</given-names></name><name><surname>Thompson</surname><given-names>RN</given-names></name><name><surname>Bisanzio</surname><given-names>D</given-names></name><name><surname>Taveira</surname><given-names>N</given-names></name><name><surname>Nax</surname><given-names>HH</given-names></name><name><surname>Pradelski</surname><given-names>BSR</given-names></name><name><surname>Nsoesie</surname><given-names>EO</given-names></name><name><surname>Murphy</surname><given-names>NR</given-names></name><name><surname>Bogoch</surname><given-names>II</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Brownstein</surname><given-names>JS</given-names></name><name><surname>Tatem</surname><given-names>AJ</given-names></name><name><surname>de Oliveira</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Sall</surname><given-names>AA</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Cauchemez</surname><given-names>S</given-names></name></person-group><article-title>Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><issue>3</issue><fpage>330</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)30513-8</pub-id><?supplied-pmid 28017559?><pub-id pub-id-type="pmid">28017559</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Stone</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>D</given-names></name></person-group><article-title>Modelling the large-scale yellow fever outbreak in Luanda, Angola, and the impact of vaccination</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><issue>1</issue><fpage>e0006158</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006158</pub-id><?supplied-pmid 29338001?><pub-id pub-id-type="pmid">29338001</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health O</collab></person-group><article-title>WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: position paper - June 2013</article-title><source>Vaccine.</source><year>2017</year><volume>35</volume><issue>43</issue><fpage>5751</fpage><lpage>5752</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.087</pub-id><pub-id pub-id-type="pmid">28689653</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">&#x02022;&#x02022; WHO. Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017&#x02013;2026. In: Organization WH, editor. Geneva 2017. p. 193&#x02013;204. The official WHO document outlining the EYE strategy formed in 2016.</mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delatorre</surname><given-names>E</given-names></name><name><surname>de Abreu</surname><given-names>FVS</given-names></name><name><surname>Ribeiro</surname><given-names>IP</given-names></name><name><surname>Gomez</surname><given-names>MM</given-names></name><name><surname>Dos Santos</surname><given-names>AAC</given-names></name><name><surname>Ferreira-de-Brito</surname><given-names>A</given-names></name><etal/></person-group><article-title>Distinct YFV lineages co-circulated in the central-western and southeastern Brazilian regions from 2015 to 2018</article-title><source>Front Microbiol</source><year>2019</year><volume>10</volume><fpage>1079</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01079</pub-id><?supplied-pmid 31178835?><pub-id pub-id-type="pmid">31178835</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faria</surname><given-names>NR</given-names></name><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Hill</surname><given-names>SC</given-names></name><name><surname>de Jesus Goes</surname><given-names>J</given-names></name><name><surname>Aguiar</surname><given-names>RS</given-names></name><name><surname>Iani</surname><given-names>FCM</given-names></name><etal/></person-group><article-title>Genomic and epidemiological monitoring of yellow fever virus transmission potential</article-title><source>Science.</source><year>2018</year><volume>361</volume><issue>6405</issue><fpage>894</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1126/science.aat7115</pub-id><?supplied-pmid 30139911?><pub-id pub-id-type="pmid">30139911</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>MDP</given-names></name><name><surname>Duarte-Neto</surname><given-names>AN</given-names></name><name><surname>Pour</surname><given-names>SZ</given-names></name><name><surname>Ortiz-Baez</surname><given-names>AS</given-names></name><name><surname>Cerny</surname><given-names>J</given-names></name><name><surname>Pereira</surname><given-names>BBS</given-names></name><etal/></person-group><article-title>Origin of the Sao Paulo yellow fever epidemic of 2017-2018 revealed through molecular epidemiological analysis of fatal cases</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>20418</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-56650-1</pub-id><?supplied-pmid 31892699?><pub-id pub-id-type="pmid">31892699</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Possas</surname><given-names>C</given-names></name><name><surname>Lourenco-de-Oliveira</surname><given-names>R</given-names></name><name><surname>Tauil</surname><given-names>PL</given-names></name><name><surname>Pinheiro</surname><given-names>FP</given-names></name><name><surname>Pissinatti</surname><given-names>A</given-names></name><name><surname>Cunha</surname><given-names>RVD</given-names></name><etal/></person-group><article-title>Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation</article-title><source>Mem Inst Oswaldo Cruz</source><year>2018</year><volume>113</volume><issue>10</issue><fpage>e180278</fpage><pub-id pub-id-type="doi">10.1590/0074-02760180278</pub-id><?supplied-pmid 30427974?><pub-id pub-id-type="pmid">30427974</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couto-Lima</surname><given-names>D</given-names></name><name><surname>Madec</surname><given-names>Y</given-names></name><name><surname>Bersot</surname><given-names>MI</given-names></name><name><surname>Campos</surname><given-names>SS</given-names></name><name><surname>Motta</surname><given-names>MA</given-names></name><name><surname>Santos</surname><given-names>FBD</given-names></name><etal/></person-group><article-title>Potential risk of re-emergence of urban transmission of yellow fever virus in Brazil facilitated by competent Aedes populations</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>4848</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-05186-3</pub-id><?supplied-pmid 28687779?><pub-id pub-id-type="pmid">28687779</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nava</surname><given-names>A</given-names></name><name><surname>Shimabukuro</surname><given-names>JS</given-names></name><name><surname>Chmura</surname><given-names>AA</given-names></name><name><surname>Luz</surname><given-names>SLB</given-names></name></person-group><article-title>The impact of global environmental changes on infectious disease emergence with a focus on risks for Brazil</article-title><source>ILAR J</source><year>2017</year><volume>58</volume><issue>3</issue><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1093/ilar/ilx034</pub-id><?supplied-pmid 29253158?><pub-id pub-id-type="pmid">29253158</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balogun</surname><given-names>EO</given-names></name><name><surname>Nok</surname><given-names>AJ</given-names></name><name><surname>Kita</surname><given-names>K</given-names></name></person-group><article-title>Global warming and the possible globalization of vector-borne diseases: a call for increased awareness and action</article-title><source>Trop Med Health</source><year>2016</year><volume>44</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s41182-016-0039-0</pub-id><?supplied-pmid 27904417?><pub-id pub-id-type="pmid">27904417</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>V</given-names></name><name><surname>Gubler</surname><given-names>DJ</given-names></name></person-group><article-title>Yellow fever: is Asia prepared for an epidemic?</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>3</issue><fpage>241</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30050-7</pub-id><?supplied-pmid 30833057?><pub-id pub-id-type="pmid">30833057</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaesser</surname><given-names>D</given-names></name><name><surname>Kester</surname><given-names>J</given-names></name><name><surname>Paulose</surname><given-names>H</given-names></name><name><surname>Alizadeh</surname><given-names>A</given-names></name><name><surname>Valentin</surname><given-names>B</given-names></name></person-group><article-title>Global travel patterns: an overview</article-title><source>J Travel Med</source><year>2017</year><volume>24</volume><issue>4</issue><fpage>tax007</fpage><pub-id pub-id-type="doi">10.1093/jtm/tax007</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Jia</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>Yellow fever virus: increasing imported cases in China</article-title><source>J Inf Secur</source><year>2016</year><volume>73</volume><issue>4</issue><fpage>377</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2016.07.003</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasserman</surname><given-names>S</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Lim</surname><given-names>PL</given-names></name></person-group><article-title>Yellow fever cases in Asia: primed for an epidemic</article-title><source>Int J Infect Dis</source><year>2016</year><volume>48</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2016.04.025</pub-id><?supplied-pmid 27156836?><pub-id pub-id-type="pmid">27156836</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Guan</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><etal/></person-group><article-title>Late or lack of vaccination linked to importation of yellow fever from Angola to China</article-title><source>Emerg Infect Dis</source><year>2018</year><volume>24</volume><issue>7</issue><fpage>1383</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.3201/eid2407.171868</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Leong</surname><given-names>WY</given-names></name></person-group><article-title>Importation of yellow fever into China: assessing travel patterns</article-title><source>J Travel Med</source><year>2017</year><volume>24</volume><issue>4</issue><fpage>tax008</fpage><pub-id pub-id-type="doi">10.1093/jtm/tax008</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julander</surname><given-names>JG</given-names></name><name><surname>Trent</surname><given-names>DW</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name></person-group><article-title>Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model</article-title><source>Vaccine.</source><year>2011</year><volume>29</volume><issue>35</issue><fpage>6008</fpage><lpage>6016</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.034</pub-id><?supplied-pmid 21718741?><pub-id pub-id-type="pmid">21718741</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotkin</surname><given-names>SA</given-names></name></person-group><article-title>Correlates of protection induced by vaccination</article-title><source>Clin Vaccine Immunol</source><year>2010</year><volume>17</volume><issue>7</issue><fpage>1055</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1128/CVI.00131-10</pub-id><?supplied-pmid 20463105?><pub-id pub-id-type="pmid">20463105</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>RA</given-names></name><name><surname>Tauraso</surname><given-names>NM</given-names></name><name><surname>Spertzel</surname><given-names>RO</given-names></name><name><surname>Ginn</surname><given-names>RK</given-names></name></person-group><article-title>Yellow fever vaccine-direct challenge of monkeys given graded doses of 17D vaccine</article-title><source>Appl Microbiol</source><year>1973</year><volume>25</volume><issue>4</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1128/AEM.25.4.539-544.1973</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanna</surname><given-names>IJ</given-names></name><name><surname>Slifka</surname><given-names>MK</given-names></name></person-group><article-title>Questions regarding the safety and duration of immunity following live yellow fever vaccination</article-title><source>Expert Rev Vaccines</source><year>2016</year><volume>15</volume><issue>12</issue><fpage>1519</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1198259</pub-id><?supplied-pmid 27267203?><pub-id pub-id-type="pmid">27267203</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonker</surname><given-names>EF</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name><name><surname>Roukens</surname><given-names>AH</given-names></name></person-group><article-title>Advances and controversies in yellow fever vaccination</article-title><source>Ther Adv Vaccines</source><year>2013</year><volume>1</volume><issue>4</issue><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1177/2051013613498954</pub-id><?supplied-pmid 24757521?><pub-id pub-id-type="pmid">24757521</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hepburn</surname><given-names>MJ</given-names></name><name><surname>Kortepeter</surname><given-names>MG</given-names></name><name><surname>Pittman</surname><given-names>PR</given-names></name><name><surname>Boudreau</surname><given-names>EF</given-names></name><name><surname>Mangiafico</surname><given-names>JA</given-names></name><name><surname>Buck</surname><given-names>PA</given-names></name><name><surname>Norris</surname><given-names>SL</given-names></name><name><surname>Anderson</surname><given-names>EL</given-names></name></person-group><article-title>Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine</article-title><source>Vaccine.</source><year>2006</year><volume>24</volume><issue>15</issue><fpage>2843</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.055</pub-id><?supplied-pmid 16494976?><pub-id pub-id-type="pmid">16494976</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>K</given-names></name><name><surname>Donnelly</surname><given-names>CA</given-names></name><name><surname>Ferguson</surname><given-names>NM</given-names></name><name><surname>Garske</surname><given-names>T</given-names></name></person-group><article-title>A meta-analysis of serological response associated with yellow fever vaccination</article-title><source>Am J Trop Med Hyg</source><year>2016</year><volume>95</volume><issue>6</issue><fpage>1435</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0401</pub-id><?supplied-pmid 27928091?><pub-id pub-id-type="pmid">27928091</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Nichols</surname><given-names>R</given-names></name><name><surname>Archambault</surname><given-names>WT</given-names></name><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Marchesani</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial</article-title><source>Am J Trop Med Hyg</source><year>2002</year><volume>66</volume><issue>5</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.4269/ajtmh.2002.66.533</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingo</surname><given-names>C</given-names></name><name><surname>Fraissinet</surname><given-names>J</given-names></name><name><surname>Ansah</surname><given-names>PO</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Bhat</surname><given-names>N</given-names></name><name><surname>Sow</surname><given-names>SO</given-names></name><etal/></person-group><article-title>Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>12</issue><fpage>1363</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(19)30323-8</pub-id><?supplied-pmid 31543249?><pub-id pub-id-type="pmid">31543249</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho</surname><given-names>LA</given-names></name><name><surname>da Silva</surname><given-names>FM</given-names></name><name><surname>da Luz Fernandes Leal</surname><given-names>M</given-names></name><name><surname>de Aguiar</surname><given-names>SG</given-names></name><name><surname>Do Nascimento</surname><given-names>JP</given-names></name><name><surname>Iguchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines- a randomized trial</article-title><source>Rev Saude Publica</source><year>2004</year><volume>38</volume><issue>5</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.1590/S0034-89102004000500009</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Noronha</surname><given-names>TG</given-names></name><name><surname>de Lourdes de Sousa</surname><given-names>MM</given-names></name><name><surname>Geraldo Leite Ribeiro</surname><given-names>J</given-names></name><name><surname>Campos Lemos</surname><given-names>JA</given-names></name><name><surname>Maria Barbosa de Lima</surname><given-names>S</given-names></name><name><surname>Martins-Filho</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Duration of post-vaccination humoral immunity against yellow fever in children</article-title><source>Vaccine.</source><year>2019</year><volume>37</volume><issue>48</issue><fpage>7147</fpage><lpage>7154</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.09.051</pub-id><?supplied-pmid 31590934?><pub-id pub-id-type="pmid">31590934</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campi-Azevedo</surname><given-names>AC</given-names></name><name><surname>Reis</surname><given-names>LR</given-names></name><name><surname>Peruhype-Magalhaes</surname><given-names>V</given-names></name><name><surname>Coelho-Dos-Reis</surname><given-names>JG</given-names></name><name><surname>Antonelli</surname><given-names>LR</given-names></name><name><surname>Fonseca</surname><given-names>CT</given-names></name><etal/></person-group><article-title>Short-lived immunity after 17DD yellow fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2192</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02192</pub-id><?supplied-pmid 31616412?><pub-id pub-id-type="pmid">31616412</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Blake LE, Garcia-Blanco MA. Human genetic variation and yellow fever mortality during 19th century U.S. epidemics. MBio. 2014;5(3). 10.1128/mBio.01253-14</mixed-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>TH</given-names></name><name><surname>Lum</surname><given-names>FM</given-names></name><name><surname>Ghaffar</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>YH</given-names></name><name><surname>Amrun</surname><given-names>SN</given-names></name><name><surname>Tan</surname><given-names>JJL</given-names></name><name><surname>Lee</surname><given-names>CYP</given-names></name><name><surname>Chua</surname><given-names>TK</given-names></name><name><surname>Carissimo</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>WWL</given-names></name><name><surname>Claser</surname><given-names>C</given-names></name><name><surname>Rajarethinam</surname><given-names>R</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name></person-group><article-title>Plasmodium co-infection protects against chikungunya virus-induced pathologies</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>3905</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06227-9</pub-id><?supplied-pmid 30254309?><pub-id pub-id-type="pmid">30254309</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muyanja</surname><given-names>E</given-names></name><name><surname>Ssemaganda</surname><given-names>A</given-names></name><name><surname>Ngauv</surname><given-names>P</given-names></name><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Perrin</surname><given-names>H</given-names></name><name><surname>Srinivasan</surname><given-names>D</given-names></name><name><surname>Canderan</surname><given-names>G</given-names></name><name><surname>Lawson</surname><given-names>B</given-names></name><name><surname>Kopycinski</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>AS</given-names></name><name><surname>Rowe</surname><given-names>DK</given-names></name><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Isern</surname><given-names>S</given-names></name><name><surname>Michael</surname><given-names>S</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Vanderford</surname><given-names>TH</given-names></name><name><surname>Castro</surname><given-names>E</given-names></name><name><surname>Pantaleo</surname><given-names>G</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Gillmour</surname><given-names>J</given-names></name><name><surname>Kiwanuka</surname><given-names>N</given-names></name><name><surname>Nanvubya</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Birungi</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Haddad</surname><given-names>EK</given-names></name><name><surname>Kaleebu</surname><given-names>P</given-names></name><name><surname>Fast</surname><given-names>P</given-names></name><name><surname>Sekaly</surname><given-names>RP</given-names></name><name><surname>Trautmann</surname><given-names>L</given-names></name><name><surname>Gaucher</surname><given-names>D</given-names></name></person-group><article-title>Immune activation alters cellular and humoral responses to yellow fever 17D vaccine</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><issue>7</issue><fpage>3147</fpage><lpage>3158</lpage><pub-id pub-id-type="doi">10.1172/JCI75429</pub-id><?supplied-pmid 24911151?><pub-id pub-id-type="pmid">24911151</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campi-Azevedo</surname><given-names>AC</given-names></name><name><surname>Costa-Pereira</surname><given-names>C</given-names></name><name><surname>Antonelli</surname><given-names>LR</given-names></name><name><surname>Fonseca</surname><given-names>CT</given-names></name><name><surname>Teixeira-Carvalho</surname><given-names>A</given-names></name><name><surname>Villela-Rezende</surname><given-names>G</given-names></name><name><surname>Santos</surname><given-names>RA</given-names></name><name><surname>Batista</surname><given-names>MA</given-names></name><name><surname>Campos</surname><given-names>FM</given-names></name><name><surname>Pacheco-Porto</surname><given-names>L</given-names></name><name><surname>Melo J&#x000fa;nior</surname><given-names>OA</given-names></name><name><surname>Hossell</surname><given-names>DMSH</given-names></name><name><surname>Coelho-dos-Reis</surname><given-names>JG</given-names></name><name><surname>Peruhype-Magalh&#x000e3;es</surname><given-names>V</given-names></name><name><surname>Costa-Silva</surname><given-names>MF</given-names></name><name><surname>de Oliveira</surname><given-names>JG</given-names></name><name><surname>Farias</surname><given-names>RH</given-names></name><name><surname>Noronha</surname><given-names>TG</given-names></name><name><surname>Lemos</surname><given-names>JA</given-names></name><name><surname>von Doellinger</surname><given-names>VR</given-names></name><name><surname>Sim&#x000f5;es</surname><given-names>M</given-names></name><name><surname>de Souza</surname><given-names>MM</given-names></name><name><surname>Malaquias</surname><given-names>LC</given-names></name><name><surname>Persi</surname><given-names>HR</given-names></name><name><surname>Pereira</surname><given-names>JM</given-names></name><name><surname>Martins</surname><given-names>JA</given-names></name><name><surname>Dornelas-Ribeiro</surname><given-names>M</given-names></name><name><surname>Vinhas</surname><given-names>AA</given-names></name><name><surname>Alves</surname><given-names>TR</given-names></name><name><surname>Maia</surname><given-names>ML</given-names></name><name><surname>Freire</surname><given-names>MS</given-names></name><name><surname>Martins</surname><given-names>RM</given-names></name><name><surname>Homma</surname><given-names>A</given-names></name><name><surname>Romano</surname><given-names>APM</given-names></name><name><surname>Domingues</surname><given-names>CM</given-names></name><name><surname>Tauil</surname><given-names>PL</given-names></name><name><surname>Vasconcelos</surname><given-names>PF</given-names></name><name><surname>Rios</surname><given-names>M</given-names></name><name><surname>Caldas</surname><given-names>IR</given-names></name><name><surname>Camacho</surname><given-names>LA</given-names></name><name><surname>Martins-Filho</surname><given-names>OA</given-names></name></person-group><article-title>Booster dose after 10 years is recommended following 17DD-YF primary vaccination</article-title><source>Hum Vaccin Immunother</source><year>2016</year><volume>12</volume><issue>2</issue><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1082693</pub-id><?supplied-pmid 26360663?><pub-id pub-id-type="pmid">26360663</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotuzzo</surname><given-names>E</given-names></name><name><surname>Yactayo</surname><given-names>S</given-names></name><name><surname>Cordova</surname><given-names>E</given-names></name></person-group><article-title>Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years</article-title><source>Am J Trop Med Hyg</source><year>2013</year><volume>89</volume><issue>3</issue><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.13-0264</pub-id><?supplied-pmid 24006295?><pub-id pub-id-type="pmid">24006295</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poland</surname><given-names>JD</given-names></name><name><surname>Calisher</surname><given-names>CH</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Downs</surname><given-names>WG</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name></person-group><article-title>Persistence of neutralizing antibody 30&#x02013;35 years after immunization with 17D yellow fever vaccine</article-title><source>Bull World Health Organ</source><year>1981</year><volume>59</volume><issue>6</issue><fpage>5</fpage></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieten</surname><given-names>RW</given-names></name><name><surname>Jonker</surname><given-names>EFF</given-names></name><name><surname>van Leeuwen</surname><given-names>EMM</given-names></name><name><surname>Remmerswaal</surname><given-names>EBM</given-names></name><name><surname>ten Berge</surname><given-names>IJM</given-names></name><name><surname>de Visser</surname><given-names>AW</given-names></name><name><surname>van Genderen</surname><given-names>PJJ</given-names></name><name><surname>Goorhuis</surname><given-names>A</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name><name><surname>Grobusch</surname><given-names>MP</given-names></name><name><surname>de Bree</surname><given-names>GJ</given-names></name></person-group><article-title>A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>3</issue><fpage>e0149871</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0149871</pub-id><?supplied-pmid 26977808?><pub-id pub-id-type="pmid">26977808</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">The World Health Organization. Lifetime validity of one dose of yellow fever vaccine: amendment to annex 7 of IHR (2005). International Health Regulations: The World Health Organization 2014.</mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Kareko BW, Booty BL, Nix CD, Lyski ZL, Slifka MK, Amanna IJ, et al. Persistence of neutralizing antibody responses among yellow fever virus 17D Vaccinees living in a nonendemic setting. J Infect Dis. 2019. 10.1093/infdis/jiz374.</mixed-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Collaborative group for studies on yellow fever v</collab></person-group><article-title>Duration of post-vaccination immunity against yellow fever in adults</article-title><source>Vaccine.</source><year>2014</year><volume>32</volume><issue>39</issue><fpage>4977</fpage><lpage>4984</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.021</pub-id><pub-id pub-id-type="pmid">25090646</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Ndeffo-Mbah ML, Pandey A. Global risk and elimination of yellow fever epidemics. J Infect Dis. 2019. 10.1093/infdis/jiz375.</mixed-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Simons</surname><given-names>H</given-names></name></person-group><article-title>Yellow fever vaccination: is one dose always enough?</article-title><source>Travel Med Infect Dis</source><year>2013</year><volume>11</volume><issue>5</issue><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2013.08.007</pub-id><?supplied-pmid 24074827?><pub-id pub-id-type="pmid">24074827</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannice</surname><given-names>K</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Hombach</surname><given-names>J</given-names></name></person-group><article-title>Fractional-dose yellow fever vaccination - advancing the evidence base</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>7</issue><fpage>603</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1803433</pub-id><?supplied-pmid 29995585?><pub-id pub-id-type="pmid">29995585</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campi-Azevedo</surname><given-names>AC</given-names></name><name><surname>de Almeida</surname><given-names>EP</given-names></name><name><surname>Coelho-Dos-Reis</surname><given-names>JG</given-names></name><name><surname>Peruhype-Magalhaes</surname><given-names>V</given-names></name><name><surname>Villela-Rezende</surname><given-names>G</given-names></name><name><surname>Quaresma</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Subdoses of 17DD yellow fever vaccine elicit equivalent virological:immunological kinetics timeline</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>391</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-14-391</pub-id><pub-id pub-id-type="pmid">25022840</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>AH</given-names></name><name><surname>Vossen</surname><given-names>AC</given-names></name><name><surname>Bredenbeek</surname><given-names>PJ</given-names></name><name><surname>van Dissel</surname><given-names>JT</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name></person-group><article-title>Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><issue>4</issue><fpage>e1993</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0001993</pub-id><?supplied-pmid 18431480?><pub-id pub-id-type="pmid">18431480</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>RM</given-names></name><name><surname>Harris</surname><given-names>JB</given-names></name><name><surname>Ahuka-Mundeke</surname><given-names>S</given-names></name><name><surname>Dixon</surname><given-names>MG</given-names></name><name><surname>Kizito</surname><given-names>GM</given-names></name><name><surname>Nsele</surname><given-names>PM</given-names></name><name><surname>Umutesi</surname><given-names>G</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Kosoy</surname><given-names>O</given-names></name><name><surname>Paluku</surname><given-names>G</given-names></name><name><surname>Gueye</surname><given-names>AS</given-names></name><name><surname>Hyde</surname><given-names>TB</given-names></name><name><surname>Ewetola</surname><given-names>R</given-names></name><name><surname>Sheria</surname><given-names>GKM</given-names></name><name><surname>Muyembe-Tamfum</surname><given-names>JJ</given-names></name><name><surname>Staples</surname><given-names>JE</given-names></name></person-group><article-title>Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>5</issue><fpage>444</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1710430</pub-id><?supplied-pmid 29443626?><pub-id pub-id-type="pmid">29443626</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>RM</given-names></name><name><surname>Maia Mde</surname><given-names>L</given-names></name><name><surname>Farias</surname><given-names>RH</given-names></name><name><surname>Camacho</surname><given-names>LA</given-names></name><name><surname>Freire</surname><given-names>MS</given-names></name><name><surname>Galler</surname><given-names>R</given-names></name><etal/></person-group><article-title>17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study</article-title><source>Hum Vaccin Immunother</source><year>2013</year><volume>9</volume><issue>4</issue><fpage>879</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.4161/hv.22982</pub-id><?supplied-pmid 23364472?><pub-id pub-id-type="pmid">23364472</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>AHE</given-names></name><name><surname>van Halem</surname><given-names>K</given-names></name><name><surname>de Visser</surname><given-names>AW</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name></person-group><article-title>Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled</article-title><source>Noninferiority Trial Ann Intern Med</source><year>2018</year><volume>169</volume><issue>11</issue><fpage>761</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.7326/M18-1529</pub-id><?supplied-pmid 30476963?><pub-id pub-id-type="pmid">30476963</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Menezes</surname><given-names>MR</given-names></name><name><surname>Maia</surname><given-names>MLS</given-names></name><name><surname>de Lima</surname><given-names>SMB</given-names></name><name><surname>de Noronha</surname><given-names>TG</given-names></name><name><surname>Xavier</surname><given-names>JR</given-names></name><name><surname>Camacho</surname><given-names>LAB</given-names></name><etal/></person-group><article-title>Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study</article-title><source>Vaccine.</source><year>2018</year><volume>36</volume><issue>28</issue><fpage>4112</fpage><lpage>4117</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.05.041</pub-id><pub-id pub-id-type="pmid">29784469</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaucher</surname><given-names>D</given-names></name><name><surname>Therrien</surname><given-names>R</given-names></name><name><surname>Kettaf</surname><given-names>N</given-names></name><name><surname>Angermann</surname><given-names>BR</given-names></name><name><surname>Boucher</surname><given-names>G</given-names></name><name><surname>Filali-Mouhim</surname><given-names>A</given-names></name><etal/></person-group><article-title>Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><issue>13</issue><fpage>3119</fpage><lpage>3131</lpage><pub-id pub-id-type="doi">10.1084/jem.20082292</pub-id><?supplied-pmid 19047440?><pub-id pub-id-type="pmid">19047440</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>EA</given-names></name><name><surname>LaFond</surname><given-names>RE</given-names></name><name><surname>Gates</surname><given-names>TJ</given-names></name><name><surname>Mai</surname><given-names>DT</given-names></name><name><surname>Malhotra</surname><given-names>U</given-names></name><name><surname>Kwok</surname><given-names>WW</given-names></name></person-group><article-title>Yellow fever vaccination elicits broad functional CD4+T cell responses that recognize structural and nonstructural proteins</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>23</issue><fpage>12794</fpage><lpage>12804</lpage><pub-id pub-id-type="doi">10.1128/jvi.01160-13</pub-id><?supplied-pmid 24049183?><pub-id pub-id-type="pmid">24049183</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>van der Most</surname><given-names>RG</given-names></name><name><surname>Akondy</surname><given-names>RS</given-names></name><name><surname>Glidewell</surname><given-names>JT</given-names></name><name><surname>Albott</surname><given-names>S</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Murali-Krishna</surname><given-names>K</given-names></name><name><surname>Mahar</surname><given-names>PL</given-names></name><name><surname>Edupuganti</surname><given-names>S</given-names></name><name><surname>Lalor</surname><given-names>S</given-names></name><name><surname>Germon</surname><given-names>S</given-names></name><name><surname>del Rio</surname><given-names>C</given-names></name><name><surname>Mulligan</surname><given-names>MJ</given-names></name><name><surname>Staprans</surname><given-names>SI</given-names></name><name><surname>Altman</surname><given-names>JD</given-names></name><name><surname>Feinberg</surname><given-names>MB</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines</article-title><source>Immunity.</source><year>2008</year><volume>28</volume><issue>5</issue><fpage>710</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.020</pub-id><?supplied-pmid 18468462?><pub-id pub-id-type="pmid">18468462</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veit</surname><given-names>O</given-names></name><name><surname>Niedrig</surname><given-names>M</given-names></name><name><surname>Chapuis-Taillard</surname><given-names>C</given-names></name><name><surname>Cavassini</surname><given-names>M</given-names></name><name><surname>Mossdorf</surname><given-names>E</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Bae</surname><given-names>HG</given-names></name><name><surname>Litzba</surname><given-names>N</given-names></name><name><surname>Staub</surname><given-names>T</given-names></name><name><surname>Hatz</surname><given-names>C</given-names></name><name><surname>Furrer</surname><given-names>H</given-names></name><collab>the Swiss HIV Cohort Study</collab></person-group><article-title>Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>5</issue><fpage>659</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1086/597006</pub-id><?supplied-pmid 19191654?><pub-id pub-id-type="pmid">19191654</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>McCarthy</surname><given-names>K</given-names></name><name><surname>Bedford</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>CT</given-names></name><name><surname>Nichols</surname><given-names>R</given-names></name><name><surname>Yoksan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical proof of principle for ChimeriVaxTM- recombinant live, attenuated vaccines against flavivirus infections</article-title><source>Vaccine.</source><year>2002</year><volume>20</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00457-1</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name></person-group><article-title>Review of the risks and benefits of yellow fever vaccination including some new analyses</article-title><source>Expert Rev Vaccines</source><year>2012</year><volume>11</volume><issue>4</issue><fpage>427</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1586/erv.12.6</pub-id><?supplied-pmid 22551029?><pub-id pub-id-type="pmid">22551029</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Weld</surname><given-names>L</given-names></name><name><surname>Tsai</surname><given-names>TF</given-names></name><name><surname>Mootrey</surname><given-names>GT</given-names></name><name><surname>Chen</surname><given-names>RT</given-names></name><name><surname>Niu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Advanced age a risk factor for illness temporally associated with yellow fever vaccination</article-title><source>Emerg Infect Dis</source><year>2001</year><volume>7</volume><issue>6</issue><fpage>7</fpage><pub-id pub-id-type="doi">10.3201/eid0706.010605</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khromava</surname><given-names>AY</given-names></name><name><surname>Eidex</surname><given-names>RB</given-names></name><name><surname>Weld</surname><given-names>LH</given-names></name><name><surname>Kohl</surname><given-names>KS</given-names></name><name><surname>Bradshaw</surname><given-names>RD</given-names></name><name><surname>Chen</surname><given-names>RT</given-names></name><name><surname>Cetron</surname><given-names>MS</given-names></name><collab>Yellow Fever Vaccine Safety Working Group</collab></person-group><article-title>Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events</article-title><source>Vaccine.</source><year>2005</year><volume>23</volume><issue>25</issue><fpage>3256</fpage><lpage>3263</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.089</pub-id><?supplied-pmid 15837230?><pub-id pub-id-type="pmid">15837230</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galler</surname><given-names>R</given-names></name><name><surname>Pugachev</surname><given-names>KV</given-names></name><name><surname>Santos</surname><given-names>CL</given-names></name><name><surname>Ocran</surname><given-names>SW</given-names></name><name><surname>Jabor</surname><given-names>AV</given-names></name><name><surname>Rodrigues</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil</article-title><source>Virology.</source><year>2001</year><volume>290</volume><issue>2</issue><fpage>309</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1168</pub-id><?supplied-pmid 11883195?><pub-id pub-id-type="pmid">11883195</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasconcelos</surname><given-names>PFC</given-names></name><name><surname>Luna</surname><given-names>EJ</given-names></name><name><surname>Galler</surname><given-names>R</given-names></name><name><surname>Silva</surname><given-names>LJ</given-names></name><name><surname>Coimbra</surname><given-names>TL</given-names></name><name><surname>Barros</surname><given-names>VLRS</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Rodigues</surname><given-names>SG</given-names></name><name><surname>Laval</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>ZG</given-names></name><name><surname>Vilela</surname><given-names>MFG</given-names></name><name><surname>Santos</surname><given-names>CLS</given-names></name><name><surname>Papaiordanou</surname><given-names>CMO</given-names></name><name><surname>Alves</surname><given-names>VAF</given-names></name><name><surname>Andrade</surname><given-names>LD</given-names></name><name><surname>Sato</surname><given-names>HK</given-names></name><name><surname>Rosa</surname><given-names>EST</given-names></name><name><surname>Froguas</surname><given-names>GB</given-names></name><name><surname>Lacava</surname><given-names>E</given-names></name><name><surname>Almeida</surname><given-names>LMR</given-names></name><name><surname>Cruz</surname><given-names>ACR</given-names></name><name><surname>Rocco</surname><given-names>IM</given-names></name><name><surname>Santos</surname><given-names>RTM</given-names></name><name><surname>Oliva</surname><given-names>OFP</given-names></name><name><surname>Yellow</surname><given-names>B</given-names></name></person-group><article-title>Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases</article-title><source>Lancet</source><year>2001</year><volume>358</volume><issue>9276</issue><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(01)05326-0</pub-id><?supplied-pmid 11463409?><pub-id pub-id-type="pmid">11463409</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzano</surname><given-names>CE</given-names></name><name><surname>Amaral</surname><given-names>E</given-names></name><name><surname>Sato</surname><given-names>HK</given-names></name><name><surname>Papaiordanou</surname><given-names>PM</given-names></name></person-group><article-title>Campinas group on yellow fever immunization during the effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil</article-title><source>Vaccine.</source><year>2006</year><volume>24</volume><issue>9</issue><fpage>1421</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.09.033</pub-id><?supplied-pmid 16236402?><pub-id pub-id-type="pmid">16236402</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasidi</surname><given-names>A</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Vandenberg</surname><given-names>J</given-names></name><name><surname>Tomori</surname><given-names>O</given-names></name><name><surname>Calisher</surname><given-names>CH</given-names></name><name><surname>Hurtgen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Yellow fever vaccination and pregnancy- a four-year prospective study</article-title><source>Trans R Soc Trop Med Hyg</source><year>1993</year><volume>87</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1016/0035-9203(93)90156-K</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassi</surname><given-names>MR</given-names></name><name><surname>Larsen</surname><given-names>MA</given-names></name><name><surname>Kongsgaard</surname><given-names>M</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>Buus</surname><given-names>S</given-names></name><name><surname>Stryhn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><issue>2</issue><fpage>e0004464</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0004464</pub-id><?supplied-pmid 26886513?><pub-id pub-id-type="pmid">26886513</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciel</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Cruz Fda</surname><given-names>S</given-names></name><name><surname>Cordeiro</surname><given-names>MT</given-names></name><name><surname>da Motta</surname><given-names>MA</given-names></name><name><surname>Cassemiro</surname><given-names>KM</given-names></name><name><surname>Maia Rde</surname><given-names>C</given-names></name><etal/></person-group><article-title>A DNA vaccine against yellow fever virus: development and evaluation</article-title><source>PLoS Negl Trop Dis</source><year>2015</year><volume>9</volume><issue>4</issue><fpage>e0003693</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0003693</pub-id><?supplied-pmid 25875109?><pub-id pub-id-type="pmid">25875109</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julander</surname><given-names>JG</given-names></name><name><surname>Testori</surname><given-names>M</given-names></name><name><surname>Cheminay</surname><given-names>C</given-names></name><name><surname>Volkmann</surname><given-names>A</given-names></name></person-group><article-title>Immunogenicity and protection after vaccination with a modified vaccinia virus Ankara-vectored yellow fever vaccine in the hamster model</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1756</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01756</pub-id><?supplied-pmid 30116244?><pub-id pub-id-type="pmid">30116244</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tottey</surname><given-names>S</given-names></name><name><surname>Shoji</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Chichester</surname><given-names>JA</given-names></name><name><surname>Green</surname><given-names>BJ</given-names></name><name><surname>Musiychuk</surname><given-names>K</given-names></name><etal/></person-group><article-title>Plant-produced subunit vaccine candidates against yellow fever induce virus neutralizing antibodies and confer protection against viral challenge in animal models</article-title><source>Am J Trop Med Hyg</source><year>2018</year><volume>98</volume><issue>2</issue><fpage>420</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0293</pub-id><?supplied-pmid 29231157?><pub-id pub-id-type="pmid">29231157</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Julander</surname><given-names>JG</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Beasley</surname><given-names>DW</given-names></name><name><surname>Watts</surname><given-names>DM</given-names></name><name><surname>Hayman</surname><given-names>E</given-names></name><name><surname>Guertin</surname><given-names>P</given-names></name><name><surname>Makowiecki</surname><given-names>J</given-names></name><name><surname>Crowell</surname><given-names>J</given-names></name><name><surname>Levesque</surname><given-names>P</given-names></name><name><surname>Bowick</surname><given-names>GC</given-names></name><name><surname>Morin</surname><given-names>M</given-names></name><name><surname>Fowler</surname><given-names>E</given-names></name><name><surname>Trent</surname><given-names>DW</given-names></name></person-group><article-title>Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity</article-title><source>Vaccine.</source><year>2010</year><volume>28</volume><issue>22</issue><fpage>3827</fpage><lpage>3840</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.03.023</pub-id><?supplied-pmid 20347059?><pub-id pub-id-type="pmid">20347059</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallas</surname><given-names>EG</given-names></name><name><surname>D'Elia Zanella</surname><given-names>L</given-names></name><name><surname>Moreira</surname><given-names>CHV</given-names></name><name><surname>Buccheri</surname><given-names>R</given-names></name><name><surname>Diniz</surname><given-names>GBF</given-names></name><name><surname>Castineiras</surname><given-names>ACP</given-names></name><etal/></person-group><article-title>Predictors of mortality in patients with yellow fever: an observational cohort study</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>7</issue><fpage>750</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30125-2</pub-id><?supplied-pmid 31104909?><pub-id pub-id-type="pmid">31104909</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>YL</given-names></name><name><surname>Joelsons</surname><given-names>D</given-names></name><name><surname>Leite</surname><given-names>GFC</given-names></name><name><surname>Malbouisson</surname><given-names>LMS</given-names></name><name><surname>Song</surname><given-names>ATW</given-names></name><name><surname>Perondi</surname><given-names>B</given-names></name><etal/></person-group><article-title>Severe yellow fever in Brazil: clinical characteristics and management</article-title><source>J Travel Med</source><year>2019</year><volume>26</volume><issue>5</issue><fpage>taz040</fpage><pub-id pub-id-type="doi">10.1093/jtm/taz040</pub-id><?supplied-pmid 31150098?><pub-id pub-id-type="pmid">31150098</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercorelli</surname><given-names>B</given-names></name><name><surname>Palu</surname><given-names>G</given-names></name><name><surname>Loregian</surname><given-names>A</given-names></name></person-group><article-title>Drug repurposing for viral infectious diseases: how far are we?</article-title><source>Trends Microbiol</source><year>2018</year><volume>26</volume><issue>10</issue><fpage>865</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.04.004</pub-id><?supplied-pmid 29759926?><pub-id pub-id-type="pmid">29759926</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacramento</surname><given-names>CQ</given-names></name><name><surname>de Melo</surname><given-names>GR</given-names></name><name><surname>de Freitas</surname><given-names>CS</given-names></name><name><surname>Rocha</surname><given-names>N</given-names></name><name><surname>Hoelz</surname><given-names>LV</given-names></name><name><surname>Miranda</surname><given-names>M</given-names></name><etal/></person-group><article-title>The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>40920</fpage><pub-id pub-id-type="doi">10.1038/srep40920</pub-id><?supplied-pmid 28098253?><pub-id pub-id-type="pmid">28098253</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HT</given-names></name><name><surname>Colby-Germinario</surname><given-names>SP</given-names></name><name><surname>Hassounah</surname><given-names>SA</given-names></name><name><surname>Fogarty</surname><given-names>C</given-names></name><name><surname>Osman</surname><given-names>N</given-names></name><name><surname>Palanisamy</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Oliveira</surname><given-names>M</given-names></name><name><surname>Quan</surname><given-names>Y</given-names></name><name><surname>Wainberg</surname><given-names>MA</given-names></name></person-group><article-title>Evaluation of Sofosbuvir (beta-D-2&#x02032;-deoxy-2&#x02032;-alpha-fluoro-2&#x02032;-beta-C-methyluridine) as an inhibitor of dengue virus replication</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>6345</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-06612-2</pub-id><?supplied-pmid 28740124?><pub-id pub-id-type="pmid">28740124</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julander</surname><given-names>JG</given-names></name><name><surname>Bantia</surname><given-names>S</given-names></name><name><surname>Taubenheim</surname><given-names>BR</given-names></name><name><surname>Minning</surname><given-names>DM</given-names></name><name><surname>Kotian</surname><given-names>P</given-names></name><name><surname>Morrey</surname><given-names>JD</given-names></name><name><surname>Smee</surname><given-names>DF</given-names></name><name><surname>Sheridan</surname><given-names>WP</given-names></name><name><surname>Babu</surname><given-names>YS</given-names></name></person-group><article-title>BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>11</issue><fpage>6607</fpage><lpage>6614</lpage><pub-id pub-id-type="doi">10.1128/AAC.03368-14</pub-id><?supplied-pmid 25155605?><pub-id pub-id-type="pmid">25155605</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Freitas</surname><given-names>CS</given-names></name><name><surname>Higa</surname><given-names>LM</given-names></name><name><surname>Sacramento</surname><given-names>CQ</given-names></name><name><surname>Ferreira</surname><given-names>AC</given-names></name><name><surname>Reis</surname><given-names>PA</given-names></name><name><surname>Delvecchio</surname><given-names>R</given-names></name><name><surname>Monteiro</surname><given-names>FL</given-names></name><name><surname>Barbosa-Lima</surname><given-names>G</given-names></name><name><surname>James Westgarth</surname><given-names>H</given-names></name><name><surname>Vieira</surname><given-names>YR</given-names></name><name><surname>Mattos</surname><given-names>M</given-names></name><name><surname>Rocha</surname><given-names>N</given-names></name><name><surname>Hoelz</surname><given-names>LVB</given-names></name><name><surname>Leme</surname><given-names>RPP</given-names></name><name><surname>Bastos</surname><given-names>MM</given-names></name><name><surname>L. Rodrigues</surname><given-names>GO</given-names></name><name><surname>M. Lopes</surname><given-names>CE</given-names></name><name><surname>Queiroz-Junior</surname><given-names>CM</given-names></name><name><surname>Lima</surname><given-names>CX</given-names></name><name><surname>Costa</surname><given-names>VV</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><name><surname>Bozza</surname><given-names>FA</given-names></name><name><surname>Bozza</surname><given-names>PT</given-names></name><name><surname>Boechat</surname><given-names>N</given-names></name><name><surname>Tanuri</surname><given-names>A</given-names></name><name><surname>Souza</surname><given-names>TML</given-names></name></person-group><article-title>Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo</article-title><source>PLoS Negl Trop Dis</source><year>2019</year><volume>13</volume><issue>1</issue><fpage>e0007072</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0007072</pub-id><?supplied-pmid 30699122?><pub-id pub-id-type="pmid">30699122</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes</surname><given-names>EA</given-names></name><name><surname>Pilger</surname><given-names>DRB</given-names></name><name><surname>Santos Nastri</surname><given-names>ACS</given-names></name><name><surname>Malta</surname><given-names>FM</given-names></name><name><surname>Pascoalino</surname><given-names>BDS</given-names></name><name><surname>Carneiro D'Albuquerque</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure</article-title><source>Ann Hepatol</source><year>2019</year><volume>18</volume><issue>6</issue><fpage>816</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.aohep.2019.09.001</pub-id><?supplied-pmid 31594756?><pub-id pub-id-type="pmid">31594756</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><mixed-citation publication-type="other">Lu X, Xiao H, Li S, Pang X, Song J, Liu S, et al. Double lock of a human neutralizing and protective monoclonal antibody targeting the yellow fever virus envelope. Cell Rep. 2019;26(2):438&#x02013;46 e5. 10.1016/j.celrep.2018.12.065.</mixed-citation></ref></ref-list></ref-list></back></article>